

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer ID6477

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company Merck Sharp & Dohme (pembrolizumab) Patient/carer groups Black Health Agency for Equality Cancer Black Care Cancer Laryngectomee Trust Cancer52 Get-A-Head Head and Neck Cancer UK Independent Cancer Patients Voice Let's Face it Macmillan Cancer Support Maggie's Centres Marie Curie Mouth Cancer Foundation National Association of Laryngectomee Clubs South Asian Health Foundation Specialised Healthcare Alliance Swallows Head & Neck Cancer Support Group Tenovus Cancer Care Healthcare professional groups Association of Cancer Physicians British Association of Head and Neck Oncologists British Association of Head and Neck Oncology Nurses British Association of Oral and Maxillofacial Surgeons	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government NHS Wales Joint Commissioning Committee Other relevant companies Amarox (cisplatin) Hospira UK (cisplatin) Sandoz (cisplatin) Possible comparator companies Hospira UK (carboplatin) Merck (cetuximab) Relevant research groups Institute of Cancer Research MRC Clinical Trials Unit
	National Institute for Health Research

Provisional stakeholder list for the evaluation of pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer ID6477 Issue date: July 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Association of Otorhinolaryngologists British Dietetic Association- Oncology Specialist Group British Geriatrics Society British Institute of Radiology British Oculoplastic Surgery Society British Psychosocial Oncology Society British Skull Base Society Cancer Research UK Oral Health Foundation Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care 	Oracle Cancer Trust Associated Public Health groups Public Health Wales UK Health Security Agency
NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Provisional stakeholder list for the evaluation of pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer ID6477 Issue date: July 2025



organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland: related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.